FIELD: biotechnology.
SUBSTANCE: oligonucleotides are described that modulate methionine sulfoxide reductase A (MSRA) expression, in particular, by targeting the interaction with the natural antisense methionine sulfoxide reductase A (MSRA) polynucleotides. This invention also relates to application of the said oligonucleotides for treatment of diseases and disorders associated with methionine sulfoxide reductase A (MSRA) expression.
EFFECT: invention expands the arsenal of tools for treatment of diseases and disorders associated with methionine sulfoxide reductase A (MSRA) expression.
28 cl, 2 dwg, 2 ex, 1 tbl
Authors
Dates
2017-05-30—Published
2011-05-25—Filed